INTEGRA LIFESCIENCES HOLDINGS CORPORATION

Integra LifeSciences Holdings Corporation

Equities

IART

US4579852082

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 21:00:00 28/06/2024 BST			5-day change	1st Jan Change
29.14 ^USD	+1.36%		-1.25%	-33.09%

06-24	Integra LifeSciences Holdings Corporation(NasdaqGS:IART) added to S&P 600 Health Care	CI
06-24	Integra LifeSciences Holdings Corporation(NasdaqGS:IART) added to S&P 600	CI

Integra LifeSciences Holdings Corporation Announces Resignation of Carrie Anderson as Chief Financial Officer, Effective from February 2, 2023

January 25, 2023 at 09:30 pm

On January 25, 2023, Carrie Anderson, Chief Financial Officer of Integra LifeSciences Holdings Corporation (the “Company”), notified the Company of her decision to resign, effective as of February 2, 2023, to pursue another professional opportunity.

Latest news about Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings Corporation(NasdaqGS:IART) added to S&P 600 Health Care	06-23	CI
Integra LifeSciences Holdings Corporation(NasdaqGS:IART) added to S&P 600	06-23	CI
Integra LifeSciences Holdings Corporation(NasdaqGS:IART) dropped from S&P 400 Health Care	06-23	CI
Integra LifeSciences Holdings Corporation(NasdaqGS:IART) dropped from S&P 400	06-23	CI
KKR & Co, CrowdStrike, GoDaddy to Join S&P 500 Index on June 24	06-10	MT
Integra Lifesciences Holdings Insider Bought Shares Worth $1,499,979, According to a Recent SEC Filing	05-24	MT
Integra Lifesciences Holdings Insider Bought Shares Worth $995,816, According to a Recent SEC Filing	05-22	MT
Sector Update: Health Care Stocks Steady Pre-Bell Friday	05-17	MT
Integra LifeSciences Holdings to Repurchase $50 Million in Shares	05-17	MT
Transcript : Integra LifeSciences Holdings Corporation Presents at Bank of America Health Care Conference 2024, May-14-2024 01:40 PM	05-14
Truist Cuts Price Target on Integra LifeSciences Holdings to $25 From $37, Keeps Hold Rating	05-07	MT
Wells Fargo Downgrades Integra LifeSciences Holdings to Equalweight From Overweight, Cuts Price Target to $25 From $45	05-07	MT
Oppenheimer Downgrades Integra LifeSciences Holdings to Perform From Outperform	05-07	MT
Tranche Update on Integra LifeSciences Holdings Corporation's Equity Buyback Plan announced on July 27, 2023.	05-06	CI
Integra LifeSciences Shares Drop to Record Low on Unexpected Loss, Boston Facility Audit Findings	05-06	DJ
Transcript : Integra LifeSciences Holdings Corporation, Q1 2024 Earnings Call, May 06, 2024	05-06
Integra LifeSciences Q1 Adjusted Earnings, Revenue Fall; Updates 2024 Outlook	05-06	MT
North American Morning Briefing : Stock Futures -2-	05-06	DJ
Integra LifeSciences Holdings Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	05-06	CI
Earnings Flash (IART) INTEGRA LIFESCIENCES HOLDINGS CORPORATION Reports Q1 Revenue $368.9M, vs. Street Est of $362M	05-06	MT
Earnings Flash (IART) INTEGRA LIFESCIENCES HOLDINGS CORPORATION Posts Q1 EPS $0.55, vs. Street Est of $0.55	05-06	MT
Integra LifeSciences Holdings Corporation Updates Earnings Guidance for the Year 2024	05-06	CI
Integra LifeSciences Holdings Corporation Provides Revenue Guidance for the Second Quarter of 2024	05-06	CI
North American Morning Briefing : Focus Turns to -2-	04-04	DJ
Citigroup Upgrades Integra LifeSciences to Neutral From Sell With $38 Price Target	04-03	MT

Chart Integra LifeSciences Holdings Corporation

Duration

Period

Chart Integra LifeSciences Holdings Corporation

More charts

Company Profile

Integra LifeSciences Holdings Corporation is a global medical technology company. The Company manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment consists of technologies and instrumentation used for a range of specialties, such as neurosurgery, neurocritical care and otolaryngology. The CSS business consists of a portfolio of brands, such as Codman, DuraGen, DuraSeal, CUSA, Mayfield, Bactiseal, and Certas Plus, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. The Company provides instruments that are used in precision, specialty and general surgical procedures. The TT segment is focused on three main areas: complex wound surgery, surgical reconstruction and peripheral nerve repair. The TT segment offers skin and wound repair, bone grafts, and nerve and tendon repair products.

Sector

Medical Equipment, Supplies & Distribution

Calendar

23/07/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Integra LifeSciences Holdings Corporation

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

28.75 USD

Average target price

34.2 USD

Spread / Average Target

+18.96%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
INTEGRA LIFESCIENCES HOLDINGS CORPORATION	-33.09%	2.27B
ABBOTT LABORATORIES	-5.60%	182B
MEDTRONIC PLC	-4.45%	102B
BECTON, DICKINSON AND COMPANY	-4.15%	66.74B
DEXCOM, INC.	-8.63%	45.55B
CENCORA, INC.	+9.70%	44.89B
HOYA CORPORATION	+6.13%	40.62B
METTLER-TOLEDO INTERNATIONAL, INC.	+15.22%	30.04B
TERUMO CORPORATION	+14.80%	24.34B
WEST PHARMACEUTICAL SERVICES, INC.	-6.46%	23.95B

Other Medical Equipment, Supplies & Distribution